TPB Q2: Stoker's Boosts Sales 25%; Debt Refinance Raises Interest Costs, SG&A Up

Turning Point Brands, Inc. (TPB) - NYSE

Snapshot - what's happening inside the company
* Revenue acceleration driven by Stoker's (modern oral) while Zig‑Zag declines; management redeployed CDS into a JV (GWO) on Jan 2, 2025.
* Balance sheet strengthened by a large debt refinancing (issued 2032 Notes) and a high cash balance; working capital rising due to higher receivables and inventory.
* Management continues ERP implementation and IT control remediation - a material weakness in ITGCs remains under remediation (expected completion by end of FY2025).

Key income‑statement and operating numbers (as reported)
* Net sales - three months ended June 30, 2025: $116,634; three months June 30, 2024: $93,225 (+25.1%).
* Net sales - six months ended June 30, 2025: $223,070; six months 2024: $176,289 (+26.5%).
* Gross profit - three months: $66,623 vs $50,398 (+32.2%). Gross margin (3mo) 57.1% vs 54.1% prior year.
* Operating income - three months: $26,327 vs $22,872 (+15.1%). Six months: $49,516 vs $42,142 (+17.5%).
* SG&A - three months: $40,296 (up $11.1M YoY, +38.0%). Six months: $76,717 (up $18.4M YoY, +31.6%).
* Interest expense, net - three months: $5,140 (was $3,042). Six months: $9,554 (was $6,521) - higher after issuance of 2032 Notes.
* Net income (consolidated) - three months: $16,960 (TPB share: $14,480). Six months: $32,751 (TPB share: $28,875).
* Diluted EPS - three months: $0.79; six months: $1.58.

Balance sheet & cash flow highlights
* Cash (unrestricted) at June 30, 2025: $109,925 (thousands). Total assets: $595,788; total liabilities: $370,965; stockholders' equity: $224,823.
* Accounts receivable, net: $30,056; Inventories, net: $105,009 (valuation allowance $18.0M).
* Notes payable and long‑term debt (carrying): $293,138 (includes $300.0M 2032 Notes issued Feb 2025; 2026 Notes redeemed).
* Operating cash flow (six months): $29,230; Investing uses: $(8,626); Financing provided $40,312 (2032 Notes proceeds net effect).
* Liquidity: $109.9M cash + $66.5M available under the 2023 ABL Facility (no borrowings outstanding under ABL at 6/30/25).

Positive aspects (income statement & operations)
* Strong top‑line growth (+25%+ YoY) driven by Stoker's modern oral - volume and mix improved margins (Stoker's gross margin 62.5% for the quarter).
* Improved consolidated gross margin (57.1% vs 54.1%) and higher operating income in absolute dollars.
* Healthy free cash inflows and large cash balance after refinancing; access to ABL capacity supports liquidity and working capital needs.
* Management reduced exposure to non‑core CDS via JV transaction, converting a segment into equity in GWO (reduces operational complexity).

Negative aspects / risks (income statement & operations)
* SG&A increased materially (+38% quarter) - shipping, selling costs for modern oral, PMTA regulatory spend ($1.6M in the quarter), ERP transition costs and elevated freight.
* Interest expense rose materially after issuing the 7.625% 2032 Notes ($300M), raising financing cost and pressuring net interest margin versus prior cheaper debt.
* Working capital tied up: A/R jumped $20.4M vs year end and inventory increased $8.8M - cash conversion could be volatile.
* Zig‑Zag segment weakness: sales and margins declined (Clipper lighter sales at discounts reduced Zig‑Zag gross profit and operating margins).
* Investment impairments: $0.9M allowance on Old Pal (and prior impairments) reflect risk in non‑core investments; investment loss volatility exists.
* Internal control material weakness (ITGCs) - still being remediated; until fixed, disclosure controls were deemed not effective and risk of reporting issues persists.
* Regulatory and litigation exposure remains a core risk (FDA PMTA process, potential product liability, tax changes like OBBBA under evaluation).

Other operational / corporate items to watch
* MSA escrow investments and exposure - MSA escrow fair value about $29.6M; related unrealized gains/losses appear in OCI.
* Dividend policy and repurchase capacity: Quarterly dividend continued (paid $0.075 on July 11, 2025). Share repurchase authorization remains $100.0M but no repurchases in H1 2025.
* Joint venture activity: contribution of SBB to GWO for 49% equity and options - could provide growth upside but adds complexity and non‑controlling interest volatility.
* ERP now implemented (April 2025) - expected to improve controls and drive efficiency if remediation and change management complete as planned.

Bottom line - short view
Turning Point Brands (NYSE: TPB) is showing solid revenue and gross‑profit growth driven by Stoker's modern oral products and has strengthened liquidity via a debt refinance. That said, rising SG&A and higher interest costs are compressing operating leverage, inventories/receivables rose, and an outstanding IT control weakness keeps execution and reporting risk on the table. Investors should watch margin sustainability in modern oral, progress on ITGC remediation, and how management converts inventory and receivables into cash while servicing higher‑cost long‑term debt.

Sources: TPB Form 10‑Q (Quarter ended June 30, 2025) - consolidated statements, notes and MD&A (figures in thousands unless otherwise noted).